Biotech

Big pharma is buying pipelines at multi-billion-dollar prices

Strategic M&A is the loudest force in biotech. Roche is reported to be acquiring Hansoh Pharmaceutical for $15B, GSK is buying Nuvalent for $10.6B at a 40% premium, and Eli Lilly paid up to $7B for in vivo CAR-T developer Kelonia and up to $1.5B for Curevo. Incyte (Vega, up to $2B), Chiesi (KalVista, $1.9B), J&J (Firefly Bio, $1B) and Merck KGaA (Silence Therapeutics, $1.1B) show the pattern also holds in the $1-2B band. Buyers are paying for de-risked clinical assets and next-generation modalities, and Lilly is the most aggressive serial acquirer. That sets a high exit bar for venture-backed biotechs.

Public listings are clearing at healthy valuations. City Therapeutics priced mid-range for a $1B fully diluted value and rose 24.4% on day one. Other recent IPOs raised $150M-$200M, including one at an $809M valuation. Earlier raises include Kailera ($625M), Odyssey ($304M), Hemab ($301.5M) and Avalyn ($300M). Crossover investors such as RA Capital sit on both sides, leading private rounds and backing the IPOs.

Why it matters · A functioning IPO market lets venture investors recycle capital and supports pricing for late-stage private rounds.

The 90-day stage mix shows Series B carrying $4.3B across 24 deals and Series D+ carrying $2.0B across 12, while 36 Series A deals totaled only $1.5B. Recent rounds include a $310M Series C from Bain Capital Life Sciences, Forbion and Novo Holdings, and $134.9M and $139.2M Series D rounds from M Ventures, Revelation Partners, Angelini and the EIB. Specialist investors such as RA Capital, 4BIO Capital and Founders Fund appear repeatedly, and Longwood Fund is targeting $150M for Fund VII.

Why it matters · Dry powder is available to proven teams, but early-stage founders face a barbell market in which a few large rounds take most of the dollars.

OpenAI's acquisition of Orchestra Bio, an AI-native drug-development operating layer, shows frontier labs moving into biotech. Isomorphic Labs' reported $45B growth valuation is described as validating the category, and a $150M Series A from a16z and F-Prime at a $1.45B valuation points the same way. Iambic's CEO, whose lead oncology drug has reached 100+ patients, argues that clinical results matter more than AI hype.

Why it matters · Value is shifting toward AI platforms that can show clinical or royalty-bearing output, so investors should separate narrative from pipeline progress.

Around $5M-$37M seed and Series A rounds continue across the market. These include an $18M seed from 4BIO Capital and IQ Capital, a $37M Series A from Sound Bioventures and HealthCap, and a $103M Series A led by RA Capital with GV, Biogen New Ventures and UPMC Enterprises. A $5.8M seed from Y Combinator and Paul Graham shows founder-class interest. Weekly deal counts reached 18-21 in the last three busy weeks.

Why it matters · A steady early pipeline feeds the next wave of Series B-C and exit candidates.